Impact of SGLT-2 inhibitors on long-term prognosis in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials
SGLT-2 inhibitors significantly reduce deaths and hospitalizations in heart failure patients with preserved function, a condition long lacking proven treatments.
This systematic review and meta-analysis of randomized controlled trials evaluates the long-term prognostic impact of SGLT-2 inhibitors in heart failure with preserved ejection fraction. The pooled evidence demonstrates significant reductions in mortality and heart failure hospitalizations, further supporting SGLT-2 inhibitor use in HFpEF — a phenotype with historically limited proven therapies.
What the study was
- Study design
- Systematic review and meta-analysis of RCTs
- Population
- Adults with heart failure with preserved ejection fraction (HFpEF)
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- American Journal of Translational Research
Why it surfaced
SR/MA of RCTs on SGLT-2 inhibitors in HFpEF delivers highest evidence tier for a cardiometabolic watchlist topic with large patient population and unmet need.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.